| Identification | More | [Name]
Veliparib (ABT-888) | [CAS]
912444-00-9 | [Synonyms]
A861695
Veliparib
NSC 737664
ABT-888 2HCl
ABT-888,Veliparib
Veliparib(chiral)
ABT-888 (Veliparib, NSC 737664)
(S)-2-(2-Methylpyrrolidin-2-yl)-1H-benimidazole-4-carboxamide
2-((R)-2-Methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide
2-[(2R)-2-Methyl-2-pyrrolidinyl]-1H-benzimidazole-7-carboxamide
2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-
carboxamide
1H-Benzimidazole-4-carboxamide, 2-((2R)-2-methyl-2-pyrrolidinyl)-
(R)-2-(2-Methylpyrrolidin-2-yl)-1H-benzo[d]iMidazole-4-carboxaMide
(R)-2-(2-Methylpyrrolidin-2-yl)-1H-benimidazole-4-carboxamide (VELIPARIB)
Veliparib
2-[(2R)-2-Methyl-2-pyrrolidinyl]-1H-benzimidazole-7-carboxamide
2-[(2R)-2-Methyl-2-pyrrolidinyl]-1H-benzimidazole-7-carboxamide Veliparib (ABT-888)
2-[(R)-2-Methylpyrrolidin-2-yl]-1H-benziMidazole-4-carboxaMide
2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benziMidazole-4-carboxaMide | [EINECS(EC#)]
681-636-1 | [Molecular Formula]
C13H16N4O.2ClH | [MDL Number]
MFCD16661059 | [MOL File]
912444-00-9.mol | [Molecular Weight]
317.218 |
| Chemical Properties | Back Directory | [Boiling point ]
579.0±40.0 °C(Predicted) | [density ]
1.274 | [storage temp. ]
Store at -20°C | [solubility ]
insoluble in H2O; ≥10.6 mg/mL in EtOH with ultrasonic; ≥6.11 mg/mL in DMSO | [form ]
solid | [pka]
9.22±0.30(Predicted) | [color ]
White to off-white | [CAS DataBase Reference]
912444-00-9 |
| Hazard Information | Back Directory | [Chemical Properties]
Off-White Solid | [Usage]
ABT-888 is a potent, orally bioavailable PARP-1/-2 inhibitor shown to potentiate DNA damaging agents. The ability to potentiate temozolomide (TMZ) and develop a biological marker for PARP inhibition was evaluated in vivo. | [Uses]
ABT-888 is a potent, orally bioavailable PARP-1/-2 inhibitor shown to potentiate DNA damaging agents. The ability to potentiate temozolomide (TMZ) and develop a biological marker for PARP inhibition was evaluated in vivo. | [Definition]
ChEBI: A benzimidazole substituted with a carbamoyl group at C-4 and a (2R)-2-methylpyrrolidin-2-yl moiety at C-2. It is a potent, orally bioavailable PARP inhibitor. | [storage]
Store at -20°C |
| Questions And Answer | Back Directory | [Abstract]
Veliparib (ABT-888) is a potential anti-cancer drug acting as a PARP inhibitor. It kills cancer cells by blocking a protein called PARP, thereby preventing the repair of DNA or genetic damage in cancer cells and possibly making them more susceptible to anticancer treatments.
Veliparib (ABT-888) is being investigated to treat squamous and non-squamous non-small cell lung cancer, BRCA breast cancer, triple negative breast cancer and ovarian cancer. | [Biological activity]
Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3. | [In vitro]
Veliparib (ABT-888) is a potential anti-cancer drug acting as a PARP inhibitor，which inhibits PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays，respectively.ABT-888 reduces clonogenic survival and inhibits DNA repair in H460 cells. ABT-888 inhibits the PARP activity with EC50 of 2 nM in C41 cells. | [In vivo]
ABT-888 inhibits PARP in B16F10 and 9L xenograft models, thus enhancing the anticancer activity of temozolomide. The Combined with other cytotoxic agents, ABT-888 shows strong antitumor effect in MX-1 xenograft model. ABT-888 reduces intratumor PAR levels by more than 95% at a dose of 3 and 12.5 mg/kg according to the the size of tumors in A375 and Colo829 xenograft models. | [Features]
ABT-888 enhances the effectiveness of common cancer treatments, such as radiation therapy and alkylating agents. | [References]
https://www.abbvie.com/our-science/pipeline/veliparib.html
https://en.wikipedia.org/wiki/Veliparib |
|
|